Alexandria Real Estate Equities, Inc. · ARE · FY2025 Q3 · Calendar Q4 2025
ARE lowers outlook as biotech demand and occupancy weaken
The supplied evidence weakens the near-term case for resilient growth: occupancy and guidance deteriorated, while liquidity and the megacampus strategy provide support for a longer-term recovery.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about ARE FY2025 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the tone shifted from confident to cautious. Guidance was lowered, occupancy weakened, venture investment gains were trending lower, and management emphasized asset sales and a narrower development focus.
Guidance delta
Lowered: the supplied analysis says 2025 FFO and rental-rate-growth guidance were reduced because of weaker occupancy and lower investment gains.
Key takeaways
- Management is shifting toward megacampus build-to-suit projects while reducing non-income-producing assets.
- The supplied analysis cites $4.2 billion of liquidity and low leverage as balance-sheet support.
- Near-term pressure includes weaker occupancy, lower venture investment gains, and delayed FDA activity.
Management priorities
- Reduce non-income-producing assets to 10%–15% of the portfolio
- Accelerate land dispositions and focus development on megacampus build-to-suit projects
- Maintain construction spending around $1.75 billion in 2026
Follow ARE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 3, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Underweight | Neutral | Downgrade | Sep 24, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Sep 21, 2026 |
| Baird | Neutral | Neutral | Maintain | Aug 24, 2026 |
| Citizens | Market Perform | Market Perform | Maintain | Aug 17, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 10, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Aug 5, 2026 |
| BNP Paribas | Underperform | Underperform | Maintain | Aug 5, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 6, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jun 12, 2026 |
| Morgan Stanley | Underweight | Equal Weight | Downgrade | Jun 11, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | May 5, 2026 |
| Jefferies | Hold | Hold | Maintain | Jan 30, 2026 |
| BTIG | Neutral | Buy | Downgrade | Oct 29, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Apr 30, 2025 |
| Wedbush | Neutral | Neutral | Maintain | Dec 6, 2024 |
| B of A Securities | Neutral | Buy | Downgrade | Jul 29, 2024 |
| Credit Suisse | Neutral | Neutral | Maintain | Oct 20, 2022 |
| CFRA | Buy | Buy | Maintain | Apr 26, 2022 |
| UBS | Neutral | Neutral | Maintain | Oct 16, 2020 |
| Berenberg | Buy | Buy | Maintain | Oct 2, 2020 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jan 14, 2020 |
| Bank of America | Buy | Neutral | Upgrade | Dec 4, 2017 |
| BTIG Research | Buy | Buy | Maintain | Aug 25, 2016 |
| ISI Group | Buy | Neutral | Upgrade | Sep 29, 2014 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $47.37. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Analyst unavailable | $59 | $53.3 | +24.6% | Sep 21, 2026 |
| Robert W. Baird | Analyst unavailable | $52 | $53.49 | +9.8% | Aug 24, 2026 |
| Evercore ISI | James Kammert | $57 | $48.14 | +20.3% | Aug 17, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $52 | $48.04 | +9.8% | Aug 5, 2026 |
| Mizuho Securities | Analyst unavailable | $60 | $51.95 | +26.7% | Jul 6, 2026 |
| BMO Capital | Analyst unavailable | $54 | $53.18 | +14.0% | Jun 12, 2026 |
| Evercore ISI | Analyst unavailable | $58 | $51.96 | +22.4% | Jun 8, 2026 |
| Morgan Stanley | Ronald Kamdem | $53 | $48.22 | +11.9% | May 26, 2026 |
| Goldman Sachs | Julien Blouin | $52 | $46.68 | +9.8% | May 19, 2026 |
| RBC Capital | Analyst unavailable | $50 | $42.32 | +5.6% | May 5, 2026 |
| Evercore ISI | Analyst unavailable | $55 | $41.21 | +16.1% | May 4, 2026 |
| Robert W. Baird | Analyst unavailable | $46 | $41.39 | -2.9% | May 4, 2026 |
| Cantor Fitzgerald | Richard Anderson | $43 | $40.41 | -9.2% | Apr 29, 2026 |
| Morgan Stanley | Analyst unavailable | $54 | $56.62 | +14.0% | Feb 10, 2026 |
| Goldman Sachs | Analyst unavailable | $60 | $54.15 | +26.7% | Feb 3, 2026 |
| Morgan Stanley | Analyst unavailable | $55 | $53.27 | +16.1% | Jan 9, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $46 | $48.97 | -2.9% | Jan 5, 2026 |
| Deutsche Bank | Omotayo Okusanya | $45 | $47.94 | -5.0% | Dec 19, 2025 |
| Jefferies | Analyst unavailable | $47 | $47.42 | -0.8% | Dec 15, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $48 | $46.84 | +1.3% | Dec 5, 2025 |
| Evercore ISI | Analyst unavailable | $64 | $46.53 | +35.1% | Dec 4, 2025 |
| BMO Capital | John Kim | $60 | $48.42 | +26.7% | Dec 4, 2025 |
| Robert W. Baird | Wesley Golladay | $67 | $48.42 | +41.4% | Dec 4, 2025 |
| Evercore ISI | Analyst unavailable | $72 | $53.84 | +52.0% | Nov 28, 2025 |
| Robert W. Baird | Wesley Golladay | $73 | $52.65 | +54.1% | Nov 26, 2025 |
| Jefferies | Joe Dickstein | $62 | $58.22 | +30.9% | Nov 3, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $79 | $74.09 | +66.8% | Oct 13, 2025 |
| BNP Paribas | Analyst unavailable | $82 | $83.46 | +73.1% | Oct 1, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $88 | $83.34 | +85.8% | Oct 1, 2025 |
| Jefferies | Peter Abramowitz | $105 | $97.55 | +121.7% | Jan 1, 2025 |
| Citigroup | Nick Joseph | $125 | $121.91 | +163.9% | Sep 12, 2024 |
| RBC Capital | Michael Carroll | $130 | $112.14 | +174.4% | Aug 5, 2024 |
| Bank of America Securities | Joshua Dennerlein | $126 | $118.92 | +166.0% | Jul 29, 2024 |
| Evercore ISI | Steve Sakwa | $126 | $115.98 | +166.0% | Jul 25, 2024 |
| Deutsche Bank | Omotayo Okusanya | $140 | $126.01 | +195.5% | Mar 5, 2024 |
| Mizuho Securities | Analyst unavailable | $172 | $133.39 | +263.1% | Jun 23, 2022 |
Track every rating change on ARE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAlexandria Real Estate Equities, Inc. (NYSE:ARE), an S&P 500® real estate investment trust, stands as the pioneering and most seasoned entity in the specialized domain of urban office properties. Since its inception in 1994, Alexandria has uniquely focused on the ownership, operation, and development of integrated campuses tailored for the life science, technology, and agtech sectors, strategically positioned within premier innovation ecosystems. By December 31, 2020, the company commanded a market capitalization of $31.9 billion and managed an extensive North American asset portfolio totaling 49.7 million square feet. This substantial base encompasses 31.9 million RSF of operational properties, 3.3 million RSF of premium Class A spaces currently under construction, 7.1 million RSF designated for near-to-mid-term development and refurbishment, and an additional 7.4 million SF earmarked for future projects.…
Historical context
All ARE earningsLatest beats and misses
Who reports nextBeat on EPS
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
Get the ARE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-03T17:40:41.091941+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-03T17:40:41.088987+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-03. For educational purposes only; not investment advice.